| Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'Day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010 | 17834 | 2010 |
| Nivolumab in Previously Untreated Melanoma without BRAF Mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6382 | 2015 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 3126 | 2015 |
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015 | 2924 | 2015 |
| Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012 | 2677 | 2012 |
| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2352 | 2018 |
| Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy LM Kranz, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, ... Nature 534 (7607), 396-401, 2016 | 1709 | 2016 |
| Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... New England Journal of Medicine 375 (19), 1845-1855, 2016 | 1521 | 2016 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... Cancer discovery 4 (1), 94-109, 2014 | 1009 | 2014 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 858 | 2017 |
| An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ... Nature 585 (7823), 107-112, 2020 | 828 | 2020 |
| Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ... European journal of cancer 60, 190-209, 2016 | 711 | 2016 |
| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 704 | 2021 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 668 | 2016 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of clinical oncology 35 (2), 226-235, 2017 | 624 | 2017 |
| Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ... European journal of cancer 60, 210-225, 2016 | 607 | 2016 |
| Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab B Weide, A Martens, JC Hassel, C Berking, MA Postow, K Bisschop, ... Clinical Cancer Research 22 (22), 5487-5496, 2016 | 603 | 2016 |
| Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ... Clinical Cancer Research 22 (12), 2908-2918, 2016 | 579 | 2016 |
| Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label … J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ... Journal of clinical oncology 36 (4), 383-390, 2018 | 557 | 2018 |
| Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy TK Eigentler, JC Hassel, C Berking, J Aberle, O Bachmann, V Grünwald, ... Cancer treatment reviews 45, 7-18, 2016 | 468 | 2016 |
